A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations

A. Bex; L. Albiges; M. Staehler; K. Bensalah; R. H. Giles; S. Dabestani; F. Hofmann; M. Hora; M. A. Kuczyk; T. B. Lam; L. Marconi; A. S. Merseburger; S. Fernandez-Pello; R. Tahbaz; Y. Abu-Ghanem; Alessandro VOLPE; B. Ljungberg; B. Escudier; T. Powles

doi:10.1016/j.eururo.2018.08.029

A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations

A. Bex
, L. Albiges
, M. Staehler
, K. Bensalah
, R. H. Giles
, S. Dabestani
, F. Hofmann
, M. Hora
, M. A. Kuczyk
, T. B. Lam
, L. Marconi
, A. S. Merseburger
, S. Fernandez-Pello
, R. Tahbaz
, Y. Abu-Ghanem
, Alessandro VOLPE
, B. Ljungberg
, B. Escudier
, T. Powles

Dipartimento di Medicina Traslazionale

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

Lingua originale	Inglese
pagine (da-a)	849-851
Numero di pagine	3
Rivista	European Urology
Volume	74
Numero di pubblicazione	6
DOI	https://doi.org/10.1016/j.eururo.2018.08.029
Stato di pubblicazione	Pubblicato - 2018

Keywords

Antineoplastic Agents, Immunological
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Renal Cell
Clinical Decision-Making
Drug Approval
Evidence-Based Medicine
Humans
Ipilimumab
Kidney Neoplasms
Nephrology
Nivolumab
Patient Selection
Treatment Outcome
Urology

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1016/j.eururo.2018.08.029

http://hdl.handle.net/11579/116359

Altri file e collegamenti

handle

Cita questo

Bex, A., Albiges, L., Staehler, M., Bensalah, K., Giles, R. H., Dabestani, S., Hofmann, F., Hora, M., Kuczyk, M. A., Lam, T. B., Marconi, L., Merseburger, A. S., Fernandez-Pello, S., Tahbaz, R., Abu-Ghanem, Y., VOLPE, A., Ljungberg, B., Escudier, B., & Powles, T. (2018). A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations. European Urology, 74(6), 849-851. https://doi.org/10.1016/j.eururo.2018.08.029

Bex, A. ; Albiges, L. ; Staehler, M. et al. / A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations. In: European Urology. 2018 ; Vol. 74, N. 6. pagg. 849-851.

@article{93b180c09dd648be9b7fc5c3fc5f7148,

title = "A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations",

keywords = "Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Clinical Decision-Making, Drug Approval, Evidence-Based Medicine, Humans, Ipilimumab, Kidney Neoplasms, Nephrology, Nivolumab, Patient Selection, Treatment Outcome, Urology, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Clinical Decision-Making, Drug Approval, Evidence-Based Medicine, Humans, Ipilimumab, Kidney Neoplasms, Nephrology, Nivolumab, Patient Selection, Treatment Outcome, Urology",

author = "A. Bex and L. Albiges and M. Staehler and K. Bensalah and Giles, \{R. H.\} and S. Dabestani and F. Hofmann and M. Hora and Kuczyk, \{M. A.\} and Lam, \{T. B.\} and L. Marconi and Merseburger, \{A. S.\} and S. Fernandez-Pello and R. Tahbaz and Y. Abu-Ghanem and Alessandro VOLPE and B. Ljungberg and B. Escudier and T. Powles",

note = "Funding Information: Conflicts of interest: Professor Dr. Thomas Powles is a company consultant for Novartis, Pfizer, and GlaxoSmithKline; has received company speaker honoraria from Novartis, Pfizer, GlaxoSmithKline, BMS, MSD, and Genentech; has participated in trials for GlaxoSmithKline, Pfizer, BMS, Genentech, and Genetech; and has received grants/research support from GlaxoSmithKline, Pfizer, and Novartis. Professor Dr. Axel Bex has received company speaker honoraria from Pfizer; has participated in trials for Pfizer Europe; has participated in advisory boards for GlaxoSmithKline and Novartis; is a company consultant for Pfizer and Novartis; and has received grants/research support from Pfizer. Professor Dr. B{\"o}rje Ljungberg has received company speaker honoraria from GlaxoSmithKline, Roche, Pfizer, and Novartis; has participated in trials for GlaxoSmithKline, Medivation, Pfizer, and Janssen R\&D; and has been on advisory boards for Pfizer and GlaxoSmithKline. Professor Dr. B. Escudier has received honorarium from BMS. Professor Dr. Laurence Albiges has received consulting/advisory fees from BMS, Pfizer, Novartis, Sanofi, Amgen, Bristol-Myers Squibb, Bayer, and Cerulean; and has received research funding from Pfizer and Novartis. Professor Dr. Karim Bensalah has received grants/research support from Pfizer and honoraria or consultation fees from Intuitive Surgical. Professor Dr. Michael Staehler is a company consultant for Pfizer, Novartis, GlaxoSmithKline, Roche, Astellas, and Bayer; has received company speaker honoraria from Pfizer, Novartis, GlaxoSmithKline, Roche, Astellas, Bayer, and Aveo; has participated in trials for Pfizer, Novartis, GlaxoSmithKline, Roche, Bayer, Aveo, Wilex, and Immatics; has received fellowships and travel grants from Pfizer, Novartis, GlaxoSmithKline, Roche, and Bayer; has received grants/research support from Pfizer, Novartis, GlaxoSmithKline, Roche, Bayer, and Aveo; and took part in the S-TRAC trial as an investigator and is an author on the S-TRAC publication. Professor Dr. Milan Hora has received company speaker honoraria from Covidien, Olympus, Janssen, and Astellas; has participated in trials for Janssen; and has received grants/research support from Ipsen. Professor Dr. Markus A. Kuczyk is a stock shareholder of Bayer Healthcare, Astellas, Storz, Pfizer, Wyeth, and Novartis; is a company consultant for Karl Storz, Coloplast, AstraZeneca, Astellas, Storz, and Hexal; has received company speaker honoraria from Pfizer, Astellas, Bayer, GlaxoSmithKline, Pierre Fabre, Janssen Cilag, and Hexal; has participated in trials for the ProtecT Study, Millenium Study C21004, Millenium Study C21005, Astellas, Ipsen, and Janssen; and has received grants/research support from Wyeth and Pfizer. Dr. Thomas B. Lam is a company consultant for and has received company speaker honoraria from Pfizer, GlaxoSmithKline, Astellas, and Ipsen. Professor Dr. Axel S. Merseburger is a company consultant for Ipsen Pharma, Bayer, Astellas, Janssen Cilag, Novartis, and Pfizer; has received company speaker honoraria from Ipsen Pharma, Wyeth, Astellas, Novartis, Pfizer, and SEP; has participated in trials for AstraZeneca, Bayer, Pfizer, TEVA, Novartis, and Astellas; has received grants/research support from Wyeth; and has participated in a company-sponsored speakers bureau for TEVA, Janssen, Pfizer, Astellas, Ferring, and Novartis. Professor Dr. Rachel H. Giles, Professor Dr. Alessandro Volpe, Dr. Saeed Dabestani, Dr. Fabian Hofmann, Dr. Lorenzo Marconi, Dr. Sergio Fern{\'a}ndez-Pello, Dr. Rana Tahbaz, and Dr. Yasmin Abu-Ghanem have nothing to disclose.",

year = "2018",

doi = "10.1016/j.eururo.2018.08.029",

language = "English",

volume = "74",

pages = "849--851",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier B.V.",

number = "6",

}

Bex, A, Albiges, L, Staehler, M, Bensalah, K, Giles, RH, Dabestani, S, Hofmann, F, Hora, M, Kuczyk, MA, Lam, TB, Marconi, L, Merseburger, AS, Fernandez-Pello, S, Tahbaz, R, Abu-Ghanem, Y, VOLPE, A, Ljungberg, B, Escudier, B & Powles, T 2018, 'A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations', European Urology, vol. 74, n. 6, pagg. 849-851. https://doi.org/10.1016/j.eururo.2018.08.029

A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations. / Bex, A.; Albiges, L.; Staehler, M. et al.
In: European Urology, Vol. 74, N. 6, 2018, pag. 849-851.

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

TY - JOUR

T1 - A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations

AU - Bex, A.

AU - Albiges, L.

AU - Staehler, M.

AU - Bensalah, K.

AU - Giles, R. H.

AU - Dabestani, S.

AU - Hofmann, F.

AU - Hora, M.

AU - Kuczyk, M. A.

AU - Lam, T. B.

AU - Marconi, L.

AU - Merseburger, A. S.

AU - Fernandez-Pello, S.

AU - Tahbaz, R.

AU - Abu-Ghanem, Y.

AU - VOLPE, Alessandro

AU - Ljungberg, B.

AU - Escudier, B.

AU - Powles, T.

N1 - Funding Information: Conflicts of interest: Professor Dr. Thomas Powles is a company consultant for Novartis, Pfizer, and GlaxoSmithKline; has received company speaker honoraria from Novartis, Pfizer, GlaxoSmithKline, BMS, MSD, and Genentech; has participated in trials for GlaxoSmithKline, Pfizer, BMS, Genentech, and Genetech; and has received grants/research support from GlaxoSmithKline, Pfizer, and Novartis. Professor Dr. Axel Bex has received company speaker honoraria from Pfizer; has participated in trials for Pfizer Europe; has participated in advisory boards for GlaxoSmithKline and Novartis; is a company consultant for Pfizer and Novartis; and has received grants/research support from Pfizer. Professor Dr. Börje Ljungberg has received company speaker honoraria from GlaxoSmithKline, Roche, Pfizer, and Novartis; has participated in trials for GlaxoSmithKline, Medivation, Pfizer, and Janssen R&D; and has been on advisory boards for Pfizer and GlaxoSmithKline. Professor Dr. B. Escudier has received honorarium from BMS. Professor Dr. Laurence Albiges has received consulting/advisory fees from BMS, Pfizer, Novartis, Sanofi, Amgen, Bristol-Myers Squibb, Bayer, and Cerulean; and has received research funding from Pfizer and Novartis. Professor Dr. Karim Bensalah has received grants/research support from Pfizer and honoraria or consultation fees from Intuitive Surgical. Professor Dr. Michael Staehler is a company consultant for Pfizer, Novartis, GlaxoSmithKline, Roche, Astellas, and Bayer; has received company speaker honoraria from Pfizer, Novartis, GlaxoSmithKline, Roche, Astellas, Bayer, and Aveo; has participated in trials for Pfizer, Novartis, GlaxoSmithKline, Roche, Bayer, Aveo, Wilex, and Immatics; has received fellowships and travel grants from Pfizer, Novartis, GlaxoSmithKline, Roche, and Bayer; has received grants/research support from Pfizer, Novartis, GlaxoSmithKline, Roche, Bayer, and Aveo; and took part in the S-TRAC trial as an investigator and is an author on the S-TRAC publication. Professor Dr. Milan Hora has received company speaker honoraria from Covidien, Olympus, Janssen, and Astellas; has participated in trials for Janssen; and has received grants/research support from Ipsen. Professor Dr. Markus A. Kuczyk is a stock shareholder of Bayer Healthcare, Astellas, Storz, Pfizer, Wyeth, and Novartis; is a company consultant for Karl Storz, Coloplast, AstraZeneca, Astellas, Storz, and Hexal; has received company speaker honoraria from Pfizer, Astellas, Bayer, GlaxoSmithKline, Pierre Fabre, Janssen Cilag, and Hexal; has participated in trials for the ProtecT Study, Millenium Study C21004, Millenium Study C21005, Astellas, Ipsen, and Janssen; and has received grants/research support from Wyeth and Pfizer. Dr. Thomas B. Lam is a company consultant for and has received company speaker honoraria from Pfizer, GlaxoSmithKline, Astellas, and Ipsen. Professor Dr. Axel S. Merseburger is a company consultant for Ipsen Pharma, Bayer, Astellas, Janssen Cilag, Novartis, and Pfizer; has received company speaker honoraria from Ipsen Pharma, Wyeth, Astellas, Novartis, Pfizer, and SEP; has participated in trials for AstraZeneca, Bayer, Pfizer, TEVA, Novartis, and Astellas; has received grants/research support from Wyeth; and has participated in a company-sponsored speakers bureau for TEVA, Janssen, Pfizer, Astellas, Ferring, and Novartis. Professor Dr. Rachel H. Giles, Professor Dr. Alessandro Volpe, Dr. Saeed Dabestani, Dr. Fabian Hofmann, Dr. Lorenzo Marconi, Dr. Sergio Fernández-Pello, Dr. Rana Tahbaz, and Dr. Yasmin Abu-Ghanem have nothing to disclose.

PY - 2018

Y1 - 2018

KW - Antineoplastic Agents, Immunological

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Carcinoma, Renal Cell

KW - Clinical Decision-Making

KW - Drug Approval

KW - Evidence-Based Medicine

KW - Humans

KW - Ipilimumab

KW - Kidney Neoplasms

KW - Nephrology

KW - Nivolumab

KW - Patient Selection

KW - Treatment Outcome

KW - Urology

KW - Antineoplastic Agents, Immunological

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Carcinoma, Renal Cell

KW - Clinical Decision-Making

KW - Drug Approval

KW - Evidence-Based Medicine

KW - Humans

KW - Ipilimumab

KW - Kidney Neoplasms

KW - Nephrology

KW - Nivolumab

KW - Patient Selection

KW - Treatment Outcome

KW - Urology

UR - https://iris.uniupo.it/handle/11579/116359

U2 - 10.1016/j.eururo.2018.08.029

DO - 10.1016/j.eururo.2018.08.029

M3 - Article

SN - 0302-2838

VL - 74

SP - 849

EP - 851

JO - European Urology

JF - European Urology

IS - 6

ER -

Bex A, Albiges L, Staehler M, Bensalah K, Giles RH, Dabestani S et al. A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations. European Urology. 2018;74(6):849-851. doi: 10.1016/j.eururo.2018.08.029